

The behavioural mistake that quietly destroys more long-term wealth in Indian retail portfolios than any other is not loss aversion, herd mentality or even recency bias — it is the simple, hard-wired compulsion to do something when the right answer is to do nothing. Behavioural scientists call this action bias. It is the reason a SIP holder cancels a perfectly working monthly investment after one bad quarter, the reason a long-term investor sells a quality compounder during a 15% correction “just to feel safer”, the reason an F&O trader places one more trade after lunch even though no setup exists, and the reason most Indian demat accounts churn their entire holdings every 14 to 18 months. Inactivity feels intolerable; activity, even when destructive, feels like progress. This article unpacks the seminal academic work on action bias, shows the Indian retail evidence, prescribes a counter-measure checklist used by Graham, Buffett, Munger and Klarman, and closes with a detailed positive case study of Titan Biotech Ltd (BSE: 524717) — whose audited FY25 numbers read like a textbook of anti-action-bias corporate behaviour.
Table of Contents
ToggleAction bias is the systematic, cross-cultural human tendency to favour action over inaction even when inaction is the statistically superior choice. The bias kicks in hardest under three conditions: (a) high uncertainty, (b) social visibility of the decision, and (c) accountability for the outcome. All three are perfectly present every time an Indian retail investor opens the Zerodha Kite app or the Groww dashboard. The market is uncertain, the brokerage platform makes activity visible (order book, P&L flashing in red and green), and the investor knows he or she will be “judged” — by themselves, by family, by Twitter — on whether they “did the right thing today”.
The behavioural cost of action bias is asymmetric. The cost of unnecessary action — brokerage, STT, GST, slippage, capital-gains tax, exit-load on mutual funds, and most importantly, the opportunity cost of breaking compounding — is large, recurring and invisible. The cost of inaction is, in most cases, zero. Yet our brains weight them in exactly the opposite direction.
The seminal academic citation on action bias is Michael Bar-Eli, Ofer H. Azar, Ilana Ritov, Yael Keidar-Levin and Galit Schein, “Action Bias Among Elite Soccer Goalkeepers: The Case of Penalty Kicks”, Journal of Economic Psychology, Volume 28, Issue 5, October 2007, pages 606–621. The authors analysed 286 penalty kicks from top professional leagues and major international tournaments. The data revealed a striking statistical reality:
The authors interviewed the goalkeepers post-match. The reason for diving was not statistical — it was psychological. Goalkeepers said it “felt worse to stand still and concede a goal than to dive and concede a goal”, even though the standing-still strategy was statistically superior. Inaction generated more regret than action, even when inaction produced better outcomes. This is the cognitive signature of action bias.

The framework has since been extended to medicine (unnecessary surgical interventions), aviation (pilot over-correction), monetary policy (Federal Reserve over-tightening), and most relevant to us — retail investing. Patel, Zeckhauser and Hendricks (1991), Odean (1999), and Barber & Odean (2000, 2001) all demonstrate that the more an investor trades, the worse their net-of-cost returns. The classic Barber–Odean finding: high-turnover individual traders underperformed low-turnover ones by 6.5 percentage points per year.
The Indian capital-market record on action bias is brutal and well-documented:
Benjamin Graham (1949, The Intelligent Investor, Chapter 8 — “The Investor and Market Fluctuations”): “The investor’s chief problem — and even his worst enemy — is likely to be himself.” Graham’s prescription was a written investment policy statement and a refusal to act on quotation movements that did not change underlying business value.
Warren Buffett (Berkshire Hathaway 1990 Letter to Shareholders): “Lethargy bordering on sloth remains the cornerstone of our investment style.” Buffett has explicitly said his ideal holding period is “forever”, and that the average annual portfolio turnover at Berkshire is in single digits. Activity is, for Buffett, the enemy of compounding.
Charlie Munger (USC Law School Commencement, 2007): “The big money is not in the buying and the selling, but in the waiting.” Munger’s contribution is sharper: he frames inactivity not as passive but as an active discipline of cognitive humility. You are not entitled to act unless you have a compelling, falsifiable, written reason.
Seth Klarman (Margin of Safety, 1991, and Baupost Group letters): Klarman keeps double-digit cash allocations specifically to resist the action-bias temptation of “putting cash to work” simply because it is sitting idle. His framework: cash is an option on future opportunity, and an option that has not been exercised is not a wasted option.

Important framing. This section is an educational case study of management process and capital-allocation patience, not a valuation verdict. Nothing in this section is a buy/sell/hold recommendation, a price target, or a comment on whether the share is cheap or expensive. The purpose is purely to illustrate, with audited FY25 numbers, what disciplined anti-action-bias corporate behaviour looks like in an Indian small-cap context.
Action bias afflicts not only investors but also corporate managements — particularly in capital allocation. Most Indian small-caps, the moment they generate a few quarters of healthy cash, rush into action: an aggressive capex announcement, a debt-funded acquisition, an unrelated diversification, a fresh QIP issuance, a buy-back at peak valuations. The cumulative cost of such action-bias capital allocation is enormous; minority shareholders pay for it for years.
Titan Biotech Ltd is, on the public record of its FY25 audited financial statements, a useful illustration of the opposite pattern — patient, sequential, cash-funded capacity build with no leverage adventurism, no unrelated diversification, and no large, lumpy capex burst. The numbers below are drawn from the company’s Annual Report 2024-25, the consolidated audited financial statements, and Screener.in.
| Marker | FY25 Audited Number | Anti-Action-Bias Behavioural Interpretation |
|---|---|---|
| Total borrowings | ₹3 crore (FY25), down from ₹16 crore (FY21) — an 81% decline | Management did not “do something” with cheap post-COVID credit. They retired debt instead of leveraging into action. |
| CFO / Operating Profit | 103% (FY25), 85% (FY24), 97% (FY23) | Cash, not accounting earnings, governs the next decision. Action-bias managements report margins; patient managements report cash. |
| Capital-Work-in-Progress (CWIP) | ₹4 crore (Sept 2025), down from a peak of ₹13 crore (FY23) | Capex is staged, executed, capitalised and only then is the next phase considered. No “announce-now-build-later” theatre. |
| Gross fixed assets | ₹57 crore (FY25), up from ₹11 crore (FY15) — a 5x sequential build over 10 years | Compounding capacity through patient annual additions, not a single debt-funded mega-project. Anti-action-bias by construction. |
| Contingent liabilities | ₹7.78 crore (FY25), down from ₹12.90 crore (FY24) — a 39.7% YoY reduction; only 5.08% of net worth | Disputes are settled, not multiplied. A management with action bias accumulates litigation; a patient management drains it. |
| Quarterly revenue trajectory | ₹46.50 Cr (Q1 FY26) → ₹54 Cr (Q2 FY26) → ₹56 Cr (Q3 FY26): three sequential QoQ increases | Growth is sequential, not pulse-driven by one-off orders. Patient operating cadence, not a quarterly action-bias scramble. |
| Board cadence | 11 directors; 4 independent (36.4%); 2 women directors (18.2%); independent chair; 14 board meetings in FY25 | A meeting roughly every four weeks signals deliberation cadence over reaction cadence — the boardroom equivalent of “schedule reviews, do not react”. |
| Director remuneration | FY25 total director remuneration ₹4.56 crore on FY25 consolidated PAT of ₹22 crore | Compensation is moderate and disclosed; no action-bias headline-grabbing pay revisions every alternate quarter. |
| Segment mix | Domestic ₹10,254.80 lakh + Overseas ₹5,390.28 lakh (~34.5% export share) | Geographic mix has been built customer-by-customer over years. No sudden export-push or domestic-blitz announcements — patient diversification, not action-bias diversification. |
Read together, the FY25 disclosures point to a corporate culture where the default is patience: ₹3 crore of total borrowings on a ₹1,779 crore market cap (at ₹430 on 15 April 2026) is the balance-sheet signature of a board that has refused, year after year, to “do something” with cheap leverage. A 10-year sales CAGR of 15% and a 10-year profit CAGR of 29%, achieved with this leverage profile, is the compounding signature of slow, deliberate, anti-action-bias capital allocation. RoCE of 16.9% and RoE of ~15% confirm that the patience has not come at the cost of capital productivity.
None of the above is a valuation call. The question of whether the share is attractively priced today is independent of, and separate from, this educational illustration of management process. The reader is requested to consult their own SEBI-registered Investment Advisor.
— Manish Goel / SEBI Registered Investment Advisor (INA100007736)
